Back to Journals » Therapeutics and Clinical Risk Management » Volume 13

Original Research

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients

       
Total article views   HTML views PDF downloads Totals
12,761 Dovepress* 11,453+ 1,790 13,243
PubMed Central* 1,308 454 1,762
Totals 12,761 2,244 15,005
*Since 29 June 2017
Total mentioned Facebook Delicious Reddit Twitter Others
4 0 0 0 0 4

View citations on PubMed Central and Google Scholar